Scancell
Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer.
Oxford, United Kingdom
57 employees
Post Ipo Equity
Total: $15.65M
Biotechnology, Health Care
General Information
Get notified when Scancell moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Scancell
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United Kingdom Market
Biotechnology
About Scancell
Taxonomy: Immunology, Cancer, ImmunoBody, Moditope, Cancer Vaccines, AvidiMab, GlyMab, Antibody Platforms, Tumours, Immune System, Cancer Treatment, Prevention, Biopharmaceuticals
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 1 |
|
01 Dec 2023 |
| Post-IPO Equity | •••••• | 1 |
|
04 Aug 2016 |
| Venture Round | •••••• | 3 |
|
25 May 2005 |
| Venture Round | •••••• | 4 |
|
27 Apr 2004 |
| Venture Round | •••••• | 1 |
|
01 Aug 1999 |
Scancell Alternatives & Competitors
Developing immune therapies to activate the body's natural defense against cancer and related diseas...
Building the next precision immunotherapies to outsmart cancer.
Cancer Healer Center provides cancer treatment using Immunotherapy that enhances the body immune sys...
FAQ About Scancell
Don't just browse. Track.
Signal Tracker monitors Scancell and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.